An Open label single arm phase I study of the pahramcokinetics and safety of Carfilzomib in subjects with advanced malignancies and varing degrees of hepatic impairment.
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Onyx Pharmaceuticals, Inc
Start Date
December 1, 2013
End Date
February 26, 2018
Administered By
Duke Cancer Institute
Awarded By
Onyx Pharmaceuticals, Inc
Start Date
December 1, 2013
End Date
February 26, 2018